The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 24th 2025
A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for Cancer Research annual meeting runs April 25-30, with the key presentations coming Sunday through Tuesday.
FGFR Inhibitors Show Promise in Cholangiocarcinoma but Face Acquired Resistance
November 25th 2022There are currently 3 FDA-approved therapies to treat cholangiocarcinoma with FGFR2 fusion or rearrangement, but these therapies face the development of resistance. Studies are underway to identify ways to overcome this resistance.
Read More
Liz Lightstone, MBBS, PhD, FRCP, professor of renal medicine for the Faculty of Medicine, Imperial College London, discussed how the potential teratogenic effects of novel therapies being investigated for lupus nephritis can impede clinical trial recruitment for women of childbearing age.
Watch
Low-Calorie Ketogenic Diet Improved Body Composition, Gut Microbiota Profile in T2D
November 23rd 2022Different dietary approaches were able to improve the state of health in patients with type 2 diabetes (T2D), with very-low-calorie ketogenic diets demonstrating better results on gut microbiota profile.
Read More
Drops in Serum Phosphate Levels May Help Predict Severe CRS After CAR T
November 23rd 2022A new study has found that a drop in serum inorganic phosphate (iP) was an early predictor of severe cytokine release syndrome (CRS), suggesting that monitoring serum iP levels could help promote safer management of the most common toxicity associated with chimeric antigen receptor (CAR) T-cell therapy.
Read More
Certain CSF Biomarker May Foretell Nusinersen Response in Children With SMA
November 22nd 2022Using data from patients with spinal muscular atrophy (SMA) type 1 and 2, researchers observed that chitotriosidase 1 levels in cerebral spinal fluid (CSF) changed over time after treatment with nusinersen, suggesting that the change could be indicative of treatment response.
Read More
New Clinical Guidelines Recommend Finerenone for CKD Associated With T2D
November 21st 2022Updated Kidney Disease: Improving Global Outcomes guidelines and a consensus report with the American Diabetes Association support the use of finerenone in certain patients who have chronic kidney disease (CKD) that may be linked to type 2 diabetes (T2D).
Read More
Dr Tochi Okwuosa: There Is a Great Need for Better CVD Risk Prediction in Cardio-Oncology
November 19th 2022In an interview at this year’s American Heart Association Scientific Sessions meeting in Chicago, Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical Center, discussed the importance of addressing cardiovascular disease (CVD) prevention in patients with cancer who are undergoing treatment.
Watch
Disease Characteristics Vary Widely Among Patients With CRSwNP or CRSsNP
November 19th 2022The investigators of this new study wanted to more clearly define the patient characteristics of the 2 main types of chronic rhinosinusitis: with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP).
Read More
Some Patients With CAD Experience Sustained Remission After Sutimlimab Discontinuation
November 18th 2022A research letter published in Blood Advances details the first clinical evidence of sustained hematologic remission for cold agglutinin disease (CAD) after sutimlimab treatment discontinuation.
Read More
As providers strive to deliver seamless, collaborative, and deeply engaging care, advances focused on treating the whole health of a person, wherever they are in their care journey, will be necessary as the health care system continues to evolve to meet the needs of patients and providers alike.
Read More
CAR T-Cell Therapy Can Work as Salvage Treatment in Relapsed MM Following BCMA-Directed CAR T
November 18th 2022New data show patients treated with chimeric antigen receptor (CAR) T-cell therapy as salvage therapy tended to have meaningful results despite treatment failure following B-cell maturation antigen (BCMA) CAR T.
Read More